Regeneron Pharmaceuticals (REGN) Income towards Parent Company (2009 - 2026)

Regeneron Pharmaceuticals has reported Income towards Parent Company for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Income towards Parent Company fell 6.81% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $4.3 billion, a 2.91% decrease from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 2.09% from the prior year.
• Income towards Parent Company was $1.3 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $727.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was $1.5 billion in Q3 2025, with the low at $722.0 million in Q1 2024.
• Average Income towards Parent Company over 5 years is $1.1 billion, with a median of $990.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 72.5% in 2022, then jumped 47.9% in 2024.
• Over 5 years, Income towards Parent Company stood at $1.2 billion in 2022, then decreased by 3.13% to $1.2 billion in 2023, then slipped by 20.86% to $917.7 million in 2024, then declined by 7.97% to $844.6 million in 2025, then jumped by 53.55% to $1.3 billion in 2026.
• The last three Income towards Parent Company figures came in at $1.3 billion (Q2 2026), $727.2 million (Q1 2026), and $844.6 million (Q4 2025), per Business Quant data.